FRA:ZOE - Deutsche Boerse Ag - US98978V1035 - Common Stock - Currency: EUR
ZOE gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. While ZOE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ZOE is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.46% | ||
ROE | 52.12% | ||
ROIC | 24.98% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 36.66% | ||
PM (TTM) | 26.86% | ||
GM | 70.68% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.09 | ||
Debt/FCF | 2.86 | ||
Altman-Z | 7.13 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.75 | ||
Quick Ratio | 1.08 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 25.58 | ||
Fwd PE | 24.49 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 29.38 | ||
EV/EBITDA | 18.62 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 1.35% |
FRA:ZOE (4/25/2025, 7:00:00 PM)
133.04
-0.66 (-0.49%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 1.35% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 25.58 | ||
Fwd PE | 24.49 | ||
P/S | 7.29 | ||
P/FCF | 29.38 | ||
P/OCF | 22.86 | ||
P/B | 14.15 | ||
P/tB | 73.46 | ||
EV/EBITDA | 18.62 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.46% | ||
ROE | 52.12% | ||
ROCE | 31.34% | ||
ROIC | 24.98% | ||
ROICexc | 30.58% | ||
ROICexgc | 54.19% | ||
OM | 36.66% | ||
PM (TTM) | 26.86% | ||
GM | 70.68% | ||
FCFM | 24.83% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.09 | ||
Debt/FCF | 2.86 | ||
Debt/EBITDA | 1.34 | ||
Cap/Depr | 131.79% | ||
Cap/Sales | 7.08% | ||
Interest Coverage | 12.38 | ||
Cash Conversion | 75.91% | ||
Profit Quality | 92.44% | ||
Current Ratio | 1.75 | ||
Quick Ratio | 1.08 | ||
Altman-Z | 7.13 |